Bristol-Myers Squibb Co (BMY) : Brown Advisory Inc reduced its stake in Bristol-Myers Squibb Co by 0.2% during the most recent quarter end. The investment management company now holds a total of 8,524,936 shares of Bristol-Myers Squibb Co which is valued at $606.8 Million after selling 16,688 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on May 13, 2016.Bristol-Myers Squibb Co makes up approximately 2.11% of Brown Advisory Inc’s portfolio.
Other Hedge Funds, Including , Mizuho Asset Managementltd. boosted its stake in BMY in the latest quarter, The investment management firm added 6,247 additional shares and now holds a total of 45,459 shares of Bristol-Myers Squibb Co which is valued at $3.2 Million. Bristol-Myers Squibb Co makes up approx 0.89% of Mizuho Asset Managementltd.’s portfolio.First City Capital Management reduced its stake in BMY by selling 1,540 shares or 3.37% in the most recent quarter. The Hedge Fund company now holds 44,208 shares of BMY which is valued at $3.1 Million. Bristol-Myers Squibb Co makes up approx 2.13% of First City Capital Management’s portfolio.Bessemer Group Inc boosted its stake in BMY in the latest quarter, The investment management firm added 242,367 additional shares and now holds a total of 2,097,895 shares of Bristol-Myers Squibb Co which is valued at $149.3 Million. Bristol-Myers Squibb Co makes up approx 0.86% of Bessemer Group Inc’s portfolio.Ingalls Snyder boosted its stake in BMY in the latest quarter, The investment management firm added 1,500 additional shares and now holds a total of 160,399 shares of Bristol-Myers Squibb Co which is valued at $11.6 Million. Bristol-Myers Squibb Co makes up approx 0.71% of Ingalls Snyder’s portfolio.
Bristol-Myers Squibb Co closed down -0.54 points or -0.76% at $70.69 with 58,15,767 shares getting traded on Wednesday. Post opening the session at $71.3, the shares hit an intraday low of $70.535 and an intraday high of $71.57 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.65. The company had revenue of $4391.00 million for the quarter, compared to analysts expectations of $4268.65 million. The company’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Initiated by Hilliard Lyons to “Neutral” on May 23, 2016. Company shares were Reiterated by UBS on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $73 .Company shares were Reiterated by Barclays on Apr 29, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $70 .
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.